These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
702 related articles for article (PubMed ID: 29882203)
1. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study. Al-Gareeb AIA; Gorial FI; Mahmood AS Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203 [TBL] [Abstract][Full Text] [Related]
2. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316 [TBL] [Abstract][Full Text] [Related]
3. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474 [TBL] [Abstract][Full Text] [Related]
4. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762 [TBL] [Abstract][Full Text] [Related]
5. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520 [TBL] [Abstract][Full Text] [Related]
6. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050 [TBL] [Abstract][Full Text] [Related]
7. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. Takeuchi T; Miyasaka N; Pedersen R; Sugiyama N; Hirose T Mod Rheumatol; 2020 Mar; 30(2):259-268. PubMed ID: 30836801 [No Abstract] [Full Text] [Related]
8. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426 [TBL] [Abstract][Full Text] [Related]
9. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T; Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649 [TBL] [Abstract][Full Text] [Related]
10. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Yamanaka H; Nagaoka S; Lee SK; Bae SC; Kasama T; Kobayashi H; Nishioka Y; Ueki Y; Seto Y; Nishinarita M; Tamura N; Kimura N; Saito K; Tomita T; Nawata Y; Suzuki S; Ishigatsubo Y; Munakata Y; Makino Y; Inoue E; Tanaka Y; Takeuchi T; Mod Rheumatol; 2016 Sep; 26(5):651-61. PubMed ID: 26698929 [TBL] [Abstract][Full Text] [Related]
11. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455 [TBL] [Abstract][Full Text] [Related]
13. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y; Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864 [TBL] [Abstract][Full Text] [Related]
14. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609 [TBL] [Abstract][Full Text] [Related]
15. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. Koyama Y; Shiraishi H; Ohta T; Uchino A Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263 [TBL] [Abstract][Full Text] [Related]
16. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428 [TBL] [Abstract][Full Text] [Related]
17. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK; J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients. Shi ZC; Fei HP; Wang ZL Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430 [TBL] [Abstract][Full Text] [Related]
19. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Emery P; Horton S; Dumitru RB; Naraghi K; van der Heijde D; Wakefield RJ; Hensor EMA; Buch MH Ann Rheum Dis; 2020 Apr; 79(4):464-471. PubMed ID: 31996367 [TBL] [Abstract][Full Text] [Related]
20. [Etanercept combined with Tripterygium wilfordii polyglycoside for treatment of rheumatoid arthritis in the elderly: a clinical study]. He WZ; Yin ZH; Gao JH; Ye ZZ; Xie Y; Kong WH; Chen YS Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Mar; 34(3):267-71. PubMed ID: 24758073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]